

**Abridgement of Time Periods under Section 2.20 of  
National Instrument 54-101 – *Communication with  
Beneficial Owners of Securities of a Reporting Issuer* ("NI 54-101")**

**VIA SEDAR**

May 4, 2020

Alberta Securities Commission  
British Columbia Securities Commission  
Ontario Securities Commission

To whom it may concern:

The undersigned, being the President and Chief Executive Officer of NexgenRx Inc. ("NexgenRx"), hereby certifies on behalf of NexgenRx and not in her personal capacity, in relation to the annual and special meeting of shareholders of NexgenRx to be held on May 27, 2020 (the "Meeting"), that:

- (a) NexgenRx has arranged to have the proxy-related materials for the Meeting sent in compliance with NI 54-101 to all beneficial owners at least 21 days before the date fixed for the Meeting; and
- (b) NexgenRx has arranged to have carried out all of the requirements of NI 54-101 in addition to those described in the above subparagraph (a).

NexgenRx is relying on Section 2.20 of NI 54-101 to abridge the time periods prescribed in subsections 2.1(b), 2.2(1) and 2.5(1) of NI 54-101.

**NEXGENRX INC.**

Per: signed "*Ronald Loucks*"  
Ronald Loucks  
President and Chief Executive Officer